Does a biotech company need a fractional CRO or a full-time CRO in 2027?

Direct Answer

The decision hinges on your company's stage, cash position, and revenue complexity. If you are pre-revenue or have under $5M in annual recurring revenue (ARR) and your go-to-market is still being defined, a fractional CRO gives you senior leadership without the long-term commitment or cash burn of a full-time hire. If you have crossed $10M+ ARR, are managing multiple sales channels, or are preparing for a fundraise or exit, a full-time CRO becomes harder to justify avoiding—but you may still start fractional to prove the model first. The honest answer is that many biotech CEOs hire fractional first and convert to full-time only when the revenue engine is validated and predictable.

Why Biotech is Different from SaaS in 2027

Biotech revenue leadership is not the same as selling software. Your buyers are often PhDs, clinicians, or procurement teams at large pharma or hospital systems. The sales cycle is long, regulatory, and relationship-intensive. A fractional CRO who has only sold SaaS will likely struggle. You need someone who understands reimbursement pathways, clinical trial timelines, KOL (key opinion leader) engagement, and partnership licensing. In 2027, many fractional CROs specialize in biotech and life sciences—they bring a network of contacts at mid-size and large pharma, which is often more valuable than generic sales methodology.

The biggest risk of hiring a fractional CRO who lacks biotech domain expertise is that they will waste months learning the market. Vet their background for specific biotech or medtech experience. Ask for references from companies at a similar stage. A generalist fractional CRO may be fine for a simple B2B SaaS tool, but for biotech, domain depth matters more.

When a Full-Time CRO Becomes Necessary

There is a point where fractional leadership hits a ceiling. That ceiling is usually defined by revenue complexity and organizational scale. If you have multiple product lines, a sales team of 10+, channel partners, and an international go-to-market, a fractional CRO working 10 days per month cannot keep up with the rhythm of weekly forecasts, pipeline reviews, deal coaching, and cross-functional alignment. In that scenario, a full-time CRO is not a luxury—it is a necessity.

Another trigger is fundraising. If you are raising a Series B or later, investors will scrutinize your revenue team. A full-time CRO signals commitment and stability. Some investors will explicitly require it. If you are planning an exit, a full-time CRO can also increase the valuation multiple by demonstrating a repeatable sales machine.

The Cost Reality: What You Actually Pay

Let’s be honest about the numbers. In 2027, a full-time CRO at a biotech company with $10M-$50M ARR will cost you:

• Base salary: $275,000–$375,000
• Bonus target: 30-50% of base
• Equity: 1-3% (often with 4-year vest, 1-year cliff)
• Benefits, payroll taxes, and recruiting fees: 20-30% on top
• Total first-year cost: $400,000–$600,000+ all-in

A fractional CRO in biotech typically charges:

• $1,000–$2,500 per day
• 4-10 days per month
• Monthly retainer: $8,000–$25,000
• No equity, no benefits, no severance

The fractional route saves you $300,000–$500,000 in the first year, which for a biotech company often means one extra clinical milestone, a key hire, or six months of runway. That is not trivial.

How to Evaluate a Fractional CRO for Biotech

When you interview fractional CROs, ask these specific questions:

• Have you sold into pharma, biotech, or hospital systems? If no, move on.
• Can you name three KOLs or pharma partners you have worked with? They should be able to, without violating NDAs.
• How do you handle a 12-18 month sales cycle? Listen for specific process, not generic "pipeline management."
• What tools do you use? Expect them to name Salesforce, HubSpot, Clari, Gong, or Outreach—but they should explain how they apply them to biotech, not just list names.
• How do you work with a founder-CEO who is also the chief scientist? This is common in biotech. The fractional CRO must be able to translate between science and business without friction.

A strong fractional CRO will also bring a network of potential hires for when you do need to build a full team. They should be able to recruit your first VP of Sales or Head of Commercial Operations from their contacts.

The Hybrid Model: Fractional Now, Full-Time Later

Many biotech CEOs in 2027 use a hybrid approach. They hire a fractional CRO for 6-12 months to:

• Build the sales playbook
• Hire the first 2-3 salespeople
• Establish CRM hygiene and reporting
• Validate pricing and packaging
• Open initial conversations with pharma partners

Once the engine is running, they convert the fractional CRO to full-time or hire a full-time VP of Sales who reports to the fractional CRO. This reduces the risk of a bad full-time hire and gives the company time to understand what they actually need.

The fractional CRO can also serve as a sounding board for the founder-CEO, who may have deep scientific expertise but limited commercial experience. That advisory role is often as valuable as the direct revenue work.

FAQ

What is the typical engagement length for a fractional CRO in biotech? Most fractional CRO engagements run 6-12 months, with monthly renewals. Some extend to 18-24 months if the company is growing fast but not ready for a full-time hire.

Can a fractional CRO work effectively if they are remote? Yes, but only if they have biotech domain experience and the company has good async communication practices. In-person visits for key meetings (board, offsites, major deals) are still expected 2-4 times per quarter.

Will a fractional CRO have conflicts of interest? Reputable fractional CROs avoid direct competitors simultaneously. They will disclose any potential conflicts upfront. Always ask for a list of current clients.

How do I measure the success of a fractional CRO? Set clear, written objectives for the first 90 days: pipeline creation, deal velocity, CRM adoption, and hiring milestones. Do not measure solely by revenue in the first quarter—biotech cycles are too long.

What happens if the fractional CRO is not working out? You terminate the contract with 30 days notice. That is the advantage of fractional—low exit cost. But do not treat it as disposable; invest in onboarding and alignment to give them a fair chance.

Do I need a fractional CRO if I already have a VP of Sales? Possibly. A fractional CRO can act as a strategic advisor and coach to your VP of Sales, especially if the VP is more operational than strategic. This is common in biotech where VPs of Sales are promoted from within.

Sources

• Pavilion – Fractional Executive Best Practices
• RevOps Co-op – Revenue Leadership Resources
• Harvard Business Review – On Fractional Leadership
• First Round Review – Hiring Senior Revenue Leaders
• SaaStr – When to Hire a CRO
• LinkedIn – Fractional CRO Community Discussions

Next step: Evaluate your current revenue stage, cash position, and go-to-market complexity. If you are leaning toward fractional, consider a 90-day pilot engagement with a fractional CRO who has biotech experience. You can find vetted candidates through CRO Syndicate or specialized biotech executive networks.

People also search for: fractional cro · hire a fractional cro · fractional cro near me · fractional cro cost